Core Viewpoint - The approval of non-naloxone by the National Medical Products Administration of China marks a significant milestone for the company, establishing it as the second domestic enterprise to receive such approval for this active pharmaceutical ingredient [1] Group 1: Company Developments - The company has received approval for non-naloxone to be registered as an active pharmaceutical ingredient for use in marketed formulations [1] - Non-naloxone is primarily used for adult patients with chronic kidney disease associated with type 2 diabetes, helping to reduce the risk of decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization due to heart failure [1] Group 2: Industry Context - The approval positions the company as a key player in the domestic pharmaceutical industry, particularly in the treatment of chronic kidney disease related to diabetes [1] - This development reflects the growing focus on chronic diseases in the healthcare sector, highlighting the importance of innovative treatments in managing such conditions [1]
石四药集团(02005.HK)：非奈利酮已获批准登记成为在上市制剂使用的原料药